[Hemodynamic and anti-ischemic effects of moexipril in patients having postinfarction heart dysfunction and moderate left ventricular heart failure].

The purpose of the study was to evaluate hemodynamic and anti-ischemic effects of moexipril in patients with postinfarction left ventricular dysfunction (PL VD) and moderate left ventricular heart failure (NYHA functional class II-III). The subjects of the study were 21 male patients (aged 52.4 +/- 1.1 years) with CHD and PLVD, related to old large-focal anterior myocardial Q-wave infarction. 4-week treatment with ACF-inhibitor moexipril in an average dose of 10.7 +/- 0.4 mg per day clinically improved the patients' condition, which was characterized by 32.2% reduction of stenocardia attack frequency (p < 0.01) and 36.4% decrease in nitroglycerin demand (p < 0.01). Activity tolerance increased by 39.2% (p < 0.001), and echoCG found a 16.5% increase of LV ejection fraction (p < 0.05). Conjunctival biomicroscopy showed that moexipril substantially improved microcirculation (MC); total conjunctival index significantly decreased by 21.7%. The results of the 4-week moexipril administration demonstrate hemodynamic and anti-ischemic effects of the new ACF inhibitor, its positive influence on transcapillary oxygen exchange and MC in patients with PLVD, associated with NYHA functional class II-III heart failure.